Pharming Group N.V.
NASDAQ:PHARBiotechnology
+$0.28 today
- Market cap
- $882.43M
- Beta
- 0.10
- P/E (TTM)
- 77.0
- EPS (TTM)
- $0.02
Volume 0.01M
Average 0.01M
Returns on capital
Pharming Group N.V. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
1.0%
avg -41.3%
ROIC
1.0%
avg -52.7%
ROA
0.6%
avg -2.4%
Analysis
ROIC is currently the strongest return metric at 1.0% versus its period average of -52.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Fabrice Chouraqui | Chief Executive Officer & Executive Director | EUR 1.84M | — | — | — |
Bruno L. Giannetti | Consultant | — | 74 | — | — |
Alexander Breidenbach | Chief Business Officer | — | 63 | — | — |
Magnus Hansson | Medical Director | — | 50 | — | — |
Kenneth Lynard EMBA | CFO & Co-Chief Executive Officer | — | 58 | — | — |
Michael Levitan | Vice President of Investor Relations & Corporate Communications | — | — | — | — |
Ruud Van Outersterp | Chief Legal & Compliance Officer and Company Secretary | — | 62 | — | — |
Ines Bernal | Chief People Officer | — | — | — | — |
Leverne Marsh | Co-CEO & Chief Commercial Officer | — | — | — | — |
Mireille Sanders | Chief Operations Officer | — | 58 | — | — |
Anurag Relan | Chief Medical Officer | — | 54 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -37.0% | +69.5% (5yr)1 analysts |
| Revenue | N/A | N/A | +22.4% | +11.2% (5yr)2 analysts |
| Net Income | N/A | N/A | -40.6% | +69.4% (5yr)2 analysts |
| EBIT | N/A | N/A | +4.6% | +24.5% (5yr)2 analysts |
Analysis
Recent growth has been strongest in Revenue at +22.4% over three years. Forward estimates point to EPS at +69.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Pharming Group N.V. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about PHAR's management, answered from reported figures.
Who manages PHAR?
Pharming Group N.V. (PHAR) lists 11 active executives. The top listed executive is Bruno L. Giannetti, Consultant.
Are PHAR insiders buying or selling?
Recent insider activity shows net buying of $3,400.00.
Continue the stock analysis
Jump to another research area for this company.